Gilead Sciences, Inc. (NASDAQ:GILD) has revealed encouraging results from its ASCENT-03 clinical trial, showcasing a major ...

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 ...

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...

From a biomarker-driven strategy to delay or avoid cystectomy, to practice-changing perioperative immunotherapy, developments ...

Gilead Sciences (NasdaqGS:GILD) recently announced positive results from its ASCENT-03 study, leading to a significant role ...